What is Esperion Therapeutics's raw materials?

Esperion Therapeutics (ESPR) reported raw materials of $100.77M in Q1 2026.

How has Esperion Therapeutics's raw materials changed year-over-year?

Esperion Therapeutics's raw materials increased by 9.7% year-over-year, from $91.84M to $100.77M.

What is the long-term trend for Esperion Therapeutics's raw materials?

Over 5 years (2020 to 2025), Esperion Therapeutics's raw materials has grown at a 48.3% compound annual growth rate (CAGR), from $13.79M to $98.77M.

What does raw materials mean?

Unprocessed materials and components purchased for use in manufacturing, valued at cost.

Esperion Therapeutics ESPR Raw materials

Raw materials at other companies

Zevra Therapeutics, Inc.ZVRA

$7K—

OrganonOGN

$13M-50.0%

AmgenAMGN

——

Regeneron PharmaceuticalsREGN

——

BridgeBio PharmaBBIO

——

ViatrisVTRS

——

Other financials

Income statement

See full

Revenue$80.1M+23.2%

Operating income-$6.6M+70.2%

Net income-$25.2M+37.7%

EPS (diluted)-$0.10+52.4%

Balance sheet

See full

Cash & equivalents$156.2M+36.2%

Total debt$155.2M+6.1%

Total equity-$307.9M+27.8%

Total assets$462.5M+42.7%

Cash flow

See full

Operating cash flow-$27.7M-22.5%

CapEx$189.0K—

Free cash flow-$27.9M-23.3%

Valuation

See full

Market cap$811.73M+283%

Enterprise value$810.81M+233%

P/S1.9×+1.1×

Profitability

See full

Operating margin18.1%+12.7pp

Net margin-34.8%+8.0pp

FCF margin-30.7%—

Returns & leverage

See full

Return on equity-260.8%—

Debt / equity0.8×—

Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InventoryRawMaterialsNetOfReserves.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's raw materials.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Esperion Therapeutics's raw materials?: Esperion Therapeutics (ESPR) reported raw materials of $100.77M in Q1 2026.
How has Esperion Therapeutics's raw materials changed year-over-year?: Esperion Therapeutics's raw materials increased by 9.7% year-over-year, from $91.84M to $100.77M.
What is the long-term trend for Esperion Therapeutics's raw materials?: Over 5 years (2020 to 2025), Esperion Therapeutics's raw materials has grown at a 48.3% compound annual growth rate (CAGR), from $13.79M to $98.77M.
What does raw materials mean?: Unprocessed materials and components purchased for use in manufacturing, valued at cost.